Patent application number | Description | Published |
20080207627 | METHODS OF PREVENTING AND REDUCING THE SEVERITY OF STRESS-ASSOCIATED CONDITIONS - The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatogical conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders. | 08-28-2008 |
20080207628 | METHODS OF PREVENTING AND REDUCING THE SEVERITY OF STRESS-ASSOCIATED CONDITIONS - The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatological conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders. | 08-28-2008 |
20090117157 | METHODS OF TREATING UROGENITAL-NEUROLOGICAL DISORDERS USING MODIFIED CLOSTRIDIAL TOXINS - The present specification discloses modified Clostridial toxins, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such modified Clostridial toxins and compositions. | 05-07-2009 |
20090232850 | THERAPEUTIC TREATMENTS USING BOTULINUM NEUROTOXIN - Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and/or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and/or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by subdermal, subcutaneous or intramuscular administration of the botulinum neurotoxin) of a patient with a coronary risk factor, respiratory disorder or arthritis. | 09-17-2009 |
20100189655 | METHODS FOR TREATING HEADACHE - A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache. | 07-29-2010 |
20100204126 | THERAPY FOR MELANIN RELATED AFFLICTIONS - Methods for treating melanin related afflictions by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a melanin related affliction. | 08-12-2010 |
20100266638 | HEADACHE TREATMENT METHOD - Herein disclosed are methods for treating headache, such as a chronic migraine for example, by administration of | 10-21-2010 |
20120244188 | Treatment of Sensory Disturbance Disorders - The present specification discloses methods of treating a sensory disturbance disorder in an individual using Targeted Endopeptidase Modulators (TEMs), compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, use of such TEMs and/or Clostridial toxins in manufacturing a medicament for treating a sensory disturbance disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a sensory disturbance disorder, use of such TEMs in treating a sensory disturbance disorder, and use of such TEMs and Clostridial toxins in treating a sensory disturbance disorder. | 09-27-2012 |
20120251515 | Endopeptidase Treatment of Cosmesis Disorders - The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a cosmesis disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a cosmesis disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a cosmesis disorder, use of such TEMs in treating a cosmesis disorder, and use of such TEMs and Clostridial toxins in treating a cosmesis disorder. | 10-04-2012 |
20120251519 | Endopeptidase Treatment of Smooth Muscle Disorders - The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a smooth muscle disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a smooth muscle disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a smooth muscle disorder, use of such TEMs in treating a smooth muscle disorder, and use of such TEMs and Clostridial toxins in treating a smooth muscle disorder. | 10-04-2012 |
20120251573 | Endopeptidase Treatment of Neuroendocrine Disorders - The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a neuroendocrine disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a neuroendocrine disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating neuroendocrine disorder, use of such TEMs in treating a neuroendocrine disorder, and use of such TEMs and Clostridial toxins in treating a neuroendocrine disorder. | 10-04-2012 |
20120251574 | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions - The present specification discloses Clostridial neurotoxins and TEMs, compositions comprising such Clostridial neurotoxins and TEMs, methods of treating a multiple medical disorder in an individual using such compositions, use of such Clostridial neurotoxins and TEMs in manufacturing a medicament for treating a multiple medical disorder, and uses of such Clostridial neurotoxins and TEMs in treating a multiple medical disorder. | 10-04-2012 |
20120251575 | Endopeptidase Treatment of Involuntary Movement Disorders - The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating an involuntary movement disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating an involuntary movement disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating an involuntary movement disorder, use of such TEMs in treating an involuntary movement disorder, and use of such TEMs and Clostridial toxins in treating an involuntary movement disorder. | 10-04-2012 |
20120258132 | Vagal Nerve-Based Disorders - The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a vagal nerve-based disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a vagal nerve-based disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a vagal nerve-based disorder, use of such TEMs in treating a vagal nerve-based disorder, and use of such TEMs and Clostridial toxins in treating a vagal nerve-based disorder. | 10-11-2012 |
20120302574 | Methods of Preventing and Reducing the Severity of Stress-Associated Conditions - The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatogical conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders. | 11-29-2012 |
20130150307 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS - Disclosed is a method for decreasing depression in a patient by local administration of a botulinum neurotoxin to the frontalis, corrugator, procereus, occipitalis, temporalis, trapezius and cervical paraspinal muscles. | 06-13-2013 |
20130217694 | METHOD OF REDUCING THE SEVERITY OF INFLAMMATORY DERMATOLOGICAL CONDITIONS - The present invention provides a method of reducing the severity of one or more symptoms of an inflammatory dermatological condition in a subject, comprising topically administering to the skin of a subject in need of such reduction an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof. | 08-22-2013 |
20130224180 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS - Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine. | 08-29-2013 |
20130251830 | THERAPEUTIC TREATMENTS USING BOTULINUM NEUROTOXIN - Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and/or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and/or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by subdermal, subcutaneous or intramuscular administration of the botulinum neurotoxin) of a patient with a coronary risk factor, respiratory disorder or arthritis. | 09-26-2013 |
20130330321 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS - Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine. | 12-12-2013 |
20140030248 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS - Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine. | 01-30-2014 |
20140170132 | PROPHYLATIC TREATMENT OF HERPES RECURRENCE - The present invention relates to methods for prophylactic treatment of Herpes recurrence with a Clostridial neurotoxin, such as a | 06-19-2014 |
20140294803 | METHODS FOR TREATING HEADACHE - A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache. | 10-02-2014 |